HealthTech & MedTech investors in the UK: the 2026 list
If you are building a HealthTech or MedTech company in the UK, the hard part of fundraising is rarely finding a list of investors. It is working out which of them actually fund health, at your stage, and understand what it takes to get a product through regulation and into a clinical or commercial setting. Pitch the wrong investor and you spend weeks educating someone who was never going to back you.
This guide sets out who is active in UK health investing in 2026, what they expect to see at each stage, and how to think about the regulatory pathway when you pitch. It draws on how Jay at PitchBuilder coaches founders to target the right people rather than the most people.
The UK HealthTech investor landscape in 2026
UK health investing splits broadly into:
- Specialists, who back medical devices, diagnostics, digital health and therapeutics as their core focus.
- Generalist technology funds that hold health in a wider portfolio.
Both can write cheques.
The difference shows up in the questions they ask and the patience they bring.
A generalist will often open on regulation: how long approval takes, what it costs, and what happens if it slips.
A specialist usually arrives with a view already formed, including a preferred route to exit. Knowing which type you are pitching, and aligning to it.
The single biggest thing I see HealthTech founders get wrong is not being able to articulate the process and cost of regulatory approval. A generalist will ask about it almost first. A specialist usually has a preferred route to exit already in mind. Make sure you and your investor are aligned on that before you pitch so you're being efficient.
What HealthTech investors expect to see at each stage
Health companies raise at very different points, from pre-clinical science to a product already selling into the NHS or private providers. Whatever the stage, investors look for a step change between rounds: a clear inflection point, new traction, or science that is meaningfully de-risked since last time.
Early on, that often means proof of the science and a credible regulatory pathway. Later it becomes clinical evidence, reimbursement progress or commercial pull.
You have to prove the science and a credible regulatory pathway. Founders come in at different stages, but an investor expects a step change, real traction or an inflection point at each round. Specialists help here, because they understand the pathways, the costs and the long-term capital a health company needs in a way generalists often do not.
Targeting the right health investor, and getting in front of them
Because health is specialised, relevance beats volume. A warm introduction mainly helps by getting your pitch deck read; it does not rescue a poor fit.
A focused cold approach to a genuinely aligned investor is perfectly reasonable, and often more productive than a warm intro to someone who does not fund your area.
The practical move is to filter for investors who fund your sub-sector and stage, check they have a relevant portfolio company, and only then reach out.
Regulation, regulation, regulation. Make sure you are pitching patient investors who understand how the system works.
Active UK HealthTech investors: a free preview
Five active funds from the PitchBuilder UK investor database are shown below, spanning stages from pre-seed to growth. Cheque sizes are each investor's own publicly stated ranges.
| Investor | Type | Stage focus | Typical cheque | Notable health investments |
|---|---|---|---|---|
| Northzone | VC fund | Pre-seed to Growth | Up to £19m | Spring Health |
| Octopus Ventures | VC fund | Pre-seed to Growth | £1m – £10m | Elvie |
| Wellington Partners | VC fund | Series A to Growth | £1.7m – £17m | SNIPR Biome, Nuclidium |
| IP Group | VC fund | Pre-seed to Growth | - | Oxford Nanopore, Centessa Pharmaceuticals |
| Science Creates Ventures | VC fund | Pre-seed to Series A | - | Open Bionics, CytoSeek |
A free preview of five funds from the PitchBuilder UK investor database. Cheque sizes are the investors' own publicly stated ranges. The full database lists more than 650 active investors, each with their application route, direct application link and current contact details, filterable by stage, sub-sector and cheque size.
How to use this list to actually get funded
A list of names is only a starting point. The founders who raise well take a shortlist like the one above, confirm each investor genuinely funds their sub-sector and stage, then tailor the approach and the pitch deck to what that investor cares about. Relevance, not volume, is what turns a list into meetings.
Before you send anything, make sure the pitch deck stands up to the questions a HealthTech investor will ask. PitchBuilder offers a pitch deck review service that tells you what an investor will think before they think it, so you walk into the room already a step ahead.
Looking for investors?
Find more than 650 active UK startup investors, in one spreadsheet.
Filter every verified investor by stage, sector and cheque size to find exactly who funds companies like yours, then apply with the direct links and contacts inside.
See what's included →Instant Download · Link Emailed to You · Excel File (.xlsx)
Frequently asked questions
How do I find HealthTech investors in the UK?
Start by targeting investors who actually fund health and medtech at your stage, rather than pitching widely. Specialist funds understand regulatory pathways and the longer capital needs; generalists can work if they already back health companies. The PitchBuilder UK investor database lets you filter by sector, stage and cheque size to build a relevant shortlist.
Do I need a specialist HealthTech investor?
Not always, but specialists tend to understand the science, the regulatory route and the costs involved, which makes conversations faster and due diligence smoother. If you approach a generalist, make sure they have a track record in health and are comfortable with your timeline to approval.
What do HealthTech investors look for at each stage?
Investors expect a step change between rounds: a clear inflection point, new traction or de-risked science. Early on that might be proof of the science and a credible regulatory pathway; later it is clinical, commercial or reimbursement progress.
How important is the regulatory pathway when raising?
Very. Founders who cannot clearly explain the process, cost and timeline to MHRA or UKCA and CE approval lose investor confidence quickly. Be clear on whether your plan is full approval or an exit before approval, and pitch investors who understand that route.
Should I use a warm introduction or a cold pitch?
Both can work. A warm introduction mainly helps get your pitch deck read, but a focused cold approach to a genuinely aligned investor is fine. Relevance beats volume every time.